Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
Rebeca Lozano, Elena Castro, Fernando López‐Campos, Heather Thorne, M. Backhaus, Isabel M. Aragón, Ylenia Cendón, Ana Gutiérrez-Pecharromán, Daniela C. Salles, Nuria Romero-Laorden, David Lorente, Pilar Gónzalez‐Peramato, Ana Calatrava, Concepción Alonso, Urbano Anido, Sara Arévalo-Lobera, Judith Balmañà, Isabel Chirivella, María José Juan-Fita, Gemma Llort, Teresa Ramón y Cajal, Elena Almagro, Daniel Alameda, Pedro P. López‐Casas, Bernardo Herrera, Joaquı́n Mateo, Colin C. Pritchard, Emmanuel S. Antonarakis, Tamara L. Lotan, J. Rubio‐Briones, Shahneen Sandhu, David Olmos (2023). Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. , 185, DOI: https://doi.org/10.1016/j.ejca.2023.02.022.
Article217 days agoImpact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
Rebeca Lozano, Elena Castro, Fernando López‐Campos, Heather Thorne, M. Backhaus, Isabel M. Aragón, Ylenia Cendón, Ana Gutiérrez-Pecharromán, Daniela C. Salles, Nuria Romero-Laorden, David Lorente, Pilar Gónzalez‐Peramato, Ana Calatrava, Concepción Alonso, Urbano Anido, Sara Arévalo-Lobera, Judith Balmañà, Isabel Chirivella, María José Juan-Fita, Gemma Llort, Teresa Ramón y Cajal, Elena Almagro, Daniel Alameda, Pedro P. López‐Casas, Bernardo Herrera, Joaquı́n Mateo, Colin C. Pritchard, Emmanuel S. Antonarakis, Tamara L. Lotan, J. Rubio‐Briones, Shahneen Sandhu, David Olmos (2023). Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. , 185, DOI: https://doi.org/10.1016/j.ejca.2023.02.022.
Article217 days agoAssociation between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
Rebeca Lozano, Daniela C. Salles, Shahneen Sandhu, Isabel M. Aragón, Heather Thorne, Fernando López‐Campos, J. Rubio‐Briones, Ana Gutiérrez-Pecharromán, Laneisha Maldonado, Tomás Di Domenico, Alejandro Sanz-Carbonell, Juan Daniel Prieto Cuadra, Isabel García, M.I. Pacheco, Teresa Garcés, Casilda Llácer, Nuria Romero-Laorden, Francisco Zambrana, Pedro P. López‐Casas, David Lorente, Joaquı́n Mateo, Colin C. Pritchard, Emmanuel S. Antonarakis, David Olmos, Tamara L. Lotan, Elena Castro (2021). Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. , 147, DOI: https://doi.org/10.1016/j.ejca.2021.01.027.
Article217 days agoValue of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Rebeca Lozano, David Lorente, Isabel M. Aragón, Nuria Romero-Laorden, Paz Nombela, Joaquı́n Mateo, Alison Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llácer, Shahneen Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, M.I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López‐Casas, Elena Castro, Johann S. de Bono, David Olmos (2021). Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. , 13(10), DOI: https://doi.org/10.3390/cancers13102334.
Article217 days ago692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
Carlo Cattrini, R. Lozano Mejorada, Vincenza Conteduca, María Dolores Martínez Ruíz, Martijn P. Lolkema, David Lorente, Shahneen Sandhu, Nuria Romero-Laorden, Yohann Loriot, Arun Azad, Luís Costa, Armelle Vinceneux, Ravindran Kanesvaran, Yüksel Ürün, Javier Puente, Gerhardt Attard, N. Mehra, Ugo De Giorgi, David Olmos, E. Castro Marcos (2020). 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.2086.
Article217 days ago